NCT06223113View on ClinicalTrials.gov

Evaluation of Safety and Performance of the EyenableTM Intraocular Lens for Cataract Treatment

NANot yet recruitingINTERVENTIONAL

Enrollment

200

Participants

Timeline

Start Date

February 29, 2024

Primary Completion Date

February 28, 2025

Study Completion Date

February 28, 2025

Conditions

Cataract

Interventions

DEVICE

EyenableTM PA60AS1 IOL

Subjects will undergo surgery to remove cataract (the cloudy lenses) via phacoemulsification, and implant the Eyedeal® EyenableTM PA60AS1 IOL in the eye capsule.

All Listed Sponsors

lead

Xi'an Eyedeal Medical Technology Co., Ltd

INDUSTRY

NCT06223113 - Evaluation of Safety and Performance of the EyenableTM Intraocular Lens for Cataract Treatment | Biotech Hunter | Biotech Hunter